FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 275 filers reported holding FATE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.99 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $21,456,000 | -18.7% | 362,000 | +19.1% | 0.42% | -10.7% |
| Q2 2021 | $26,384,000 | +5.3% | 304,000 | 0.0% | 0.47% | -11.0% |
| Q1 2021 | $25,065,000 | -51.1% | 304,000 | -46.1% | 0.53% | -48.0% |
| Q4 2020 | $51,291,000 | +92.1% | 564,067 | -15.6% | 1.01% | +56.0% |
| Q3 2020 | $26,703,000 | -14.8% | 668,067 | -26.9% | 0.65% | -28.8% |
| Q2 2020 | $31,352,000 | -12.7% | 913,775 | -43.5% | 0.91% | -19.9% |
| Q1 2020 | $35,913,000 | -8.4% | 1,616,993 | -19.3% | 1.14% | -8.8% |
| Q4 2019 | $39,191,000 | +29.2% | 2,002,605 | +2.5% | 1.25% | +1.1% |
| Q3 2019 | $30,328,000 | -12.3% | 1,952,897 | +14.7% | 1.24% | -0.5% |
| Q2 2019 | $34,569,000 | +15.5% | 1,702,897 | 0.0% | 1.24% | +8.3% |
| Q1 2019 | $29,920,000 | +40.9% | 1,702,897 | +2.9% | 1.15% | +34.9% |
| Q4 2018 | $21,232,000 | +11.1% | 1,654,865 | +41.0% | 0.85% | +24.1% |
| Q3 2018 | $19,118,000 | – | 1,173,617 | – | 0.68% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |